Front Range Biosciences, an agricultural biotech company that specializes in high-value crops like cannabis and hemp, announced this week its acquisition of Steep Hill’s Genomics Research & Development team.
Through this partnership, FRB will further build out its IP library and accelerate key research in the pursuit of healthy and dependable crop yields. Ultimately, this allows FRB to continue providing unique and advantaged cannabis and hemp varieties to farmers and growers, further supporting the industrial hemp market, which is projected to hit $20 billion in 2024.
“To partner with an esteemed group like Steep Hill represents a pivotal moment in our company’s life cycle, as well as the industry overall,” said Dr. Jonathan Vaught, CEO and Co-Founder of FRB. “The more leaders we can have come together and collaborate for the advancement of the space, the better.”
Related Links:
Big Opportunities: Michigan Cannabis Market 'Could Easily Eclipse $2B'
Green Peak Joins Forces With Michigan-Based Short's Brewing To Create Cannabis-Infused Beer, Edibles
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
